manufacturing base of Novo Nordisk pharmaceutical company in Tianjin-Xinhua

An anti-diabetic injection production line is pictured in a workshop of Novo Nordisk (China) Pharmaceutical Co., Ltd. in Tianjin, north China, Sept. 22, 2022. Over the past 20 years, Novo Nordisk, a pharmaceutical company from Denmark has been steadily increasing its investment in China. Today, Novo Nordisk has already established a full value chain in the country, with one of its largest manufacturing bases in Tianjin supplying the Chinese and international markets with durable insulin injection devices and insulin products. (Xinhua/Li Ran)

A staff member works in a laboratory of Novo Nordisk (China) Pharmaceutical Co., Ltd. in Tianjin, north China, Sept. 22, 2022. Over the past 20 years, Novo Nordisk, a Danish pharmaceutical company, has steadily increased its investment in China. Today, Novo Nordisk has already established a full value chain in the country, with one of its largest manufacturing bases in Tianjin supplying the Chinese and international markets with durable insulin injection devices and insulin products. (Xinhua/Li Ran)

A staff member works in a workshop of Novo Nordisk (China) Pharmaceutical Co., Ltd. in Tianjin, north China, Sept. 22, 2022. Over the past 20 years, Novo Nordisk, a Danish pharmaceutical company, has steadily increased its investment in China. Today, Novo Nordisk has already established a full value chain in the country, with one of its largest manufacturing bases in Tianjin supplying the Chinese and international markets with durable insulin injection devices and insulin products. (Xinhua/Li Ran)

Staff members work in a workshop of Novo Nordisk (China) Pharmaceutical Co., Ltd. in Tianjin, north China, Sept. 22, 2022. Over the past 20 years, Novo Nordisk, a Danish pharmaceutical company, has steadily increased its investment in China. Today, Novo Nordisk has already established a full value chain in the country, with one of its largest manufacturing bases in Tianjin supplying the Chinese and international markets with durable insulin injection devices and insulin products. (Xinhua/Li Ran)

Staff members work in a workshop of Novo Nordisk (China) Pharmaceutical Co., Ltd. in Tianjin, north China, Sept. 22, 2022. Over the past 20 years, Novo Nordisk, a Danish pharmaceutical company, has steadily increased its investment in China. Today, Novo Nordisk has already established a full value chain in the country, with one of its largest manufacturing bases in Tianjin supplying the Chinese and international markets with durable insulin injection devices and insulin products. (Xinhua/Li Ran)

A film packaging robot performs packaging operation in a workshop of Novo Nordisk (China) Pharmaceutical Co., Ltd. in Tianjin, north China, Sept. 22, 2022. Over the past 20 years, Novo Nordisk, a Danish pharmaceutical company, has steadily increased its investment in China. Today, Novo Nordisk has already established a full value chain in the country, with one of its largest manufacturing bases in Tianjin supplying the Chinese and international markets with durable insulin injection devices and insulin products. (Xinhua/Li Ran)

A staff member works in a laboratory of Novo Nordisk (China) Pharmaceutical Co., Ltd. in Tianjin, north China, Sept. 22, 2022. Over the past 20 years, Novo Nordisk, a Danish pharmaceutical company, has steadily increased its investment in China. Today, Novo Nordisk has already established a full value chain in the country, with one of its largest manufacturing bases in Tianjin supplying the Chinese and international markets with durable insulin injection devices and insulin products. (Xinhua/Li Ran)